MX2009008918A - Activacion de celulas que presentan antigeno humano a traves de clec-6. - Google Patents

Activacion de celulas que presentan antigeno humano a traves de clec-6.

Info

Publication number
MX2009008918A
MX2009008918A MX2009008918A MX2009008918A MX2009008918A MX 2009008918 A MX2009008918 A MX 2009008918A MX 2009008918 A MX2009008918 A MX 2009008918A MX 2009008918 A MX2009008918 A MX 2009008918A MX 2009008918 A MX2009008918 A MX 2009008918A
Authority
MX
Mexico
Prior art keywords
clec
activation
presenting cells
human antigen
antigen
Prior art date
Application number
MX2009008918A
Other languages
English (en)
Inventor
Jacques F Banchereau
Sangkon Oh
Gerard Zurawski
Sandra Zurawski
Dapeng Li
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of MX2009008918A publication Critical patent/MX2009008918A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Abstract

La presente invención incluye composiciones y métodos para utilizar nuevos anticuerpos anti-CLEC-6 y fragmentos de los mismos para modular la actividad de células inmunes.
MX2009008918A 2007-02-23 2008-02-22 Activacion de celulas que presentan antigeno humano a traves de clec-6. MX2009008918A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89141807P 2007-02-23 2007-02-23
PCT/US2008/054785 WO2008103947A2 (en) 2007-02-23 2008-02-22 Activation of human antigen-presenting cells through clec-6

Publications (1)

Publication Number Publication Date
MX2009008918A true MX2009008918A (es) 2009-09-14

Family

ID=39710781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008918A MX2009008918A (es) 2007-02-23 2008-02-22 Activacion de celulas que presentan antigeno humano a traves de clec-6.

Country Status (14)

Country Link
US (1) US20080254047A1 (es)
EP (1) EP2129692A4 (es)
JP (1) JP2010519313A (es)
KR (1) KR20090118981A (es)
CN (2) CN102586186A (es)
AU (1) AU2008218184B2 (es)
BR (1) BRPI0807613A2 (es)
CA (1) CA2717656A1 (es)
IL (2) IL200526A0 (es)
MX (1) MX2009008918A (es)
NZ (2) NZ579238A (es)
TW (1) TW200900078A (es)
WO (1) WO2008103947A2 (es)
ZA (1) ZA200906618B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012833A (es) * 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2861987B1 (en) * 2012-06-14 2016-04-27 Erasmus University Medical Center Rotterdam Methods, reagents and kits for detecting minimal residual disease
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
JP7032304B2 (ja) 2015-07-28 2022-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用
CN105510598A (zh) * 2015-12-31 2016-04-20 中国科学院海洋研究所 长牡蛎CgNatterin-3重组蛋白的应用
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EP3835322A3 (en) 2016-06-08 2021-10-06 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US20200002421A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
EP3950709B1 (en) * 2016-10-21 2024-02-14 OSE Immunotherapeutics Methods for promoting t cells response
CA3064697A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
JP2020526482A (ja) * 2017-06-28 2020-08-31 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー デクチン−２刺激及び癌免疫療法のための方法及び組成物
CN117004573A (zh) * 2017-12-13 2023-11-07 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN110373385A (zh) * 2019-07-12 2019-10-25 赛德特生物科技开发有限公司 改善神经细胞功能的免疫细胞培养基及其制备方法与应用
AU2021285992A1 (en) 2020-06-04 2023-01-05 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114315990B (zh) * 2022-03-10 2022-05-27 北京康乐卫士生物技术股份有限公司 新型冠状病毒特异性单克隆抗体的制备及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) * 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) * 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
WO2003073827A2 (en) * 2002-02-28 2003-09-12 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US7666596B2 (en) * 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
DK2114985T3 (en) * 2007-02-02 2015-03-30 Baylor Res Inst Complexes of multivariable antigens and target antibody, a humanized

Also Published As

Publication number Publication date
NZ579238A (en) 2012-04-27
CN102586186A (zh) 2012-07-18
TW200900078A (en) 2009-01-01
EP2129692A4 (en) 2010-12-15
US20080254047A1 (en) 2008-10-16
NZ595319A (en) 2012-09-28
KR20090118981A (ko) 2009-11-18
BRPI0807613A2 (pt) 2014-06-10
WO2008103947A2 (en) 2008-08-28
CA2717656A1 (en) 2008-08-28
CN101668777A (zh) 2010-03-10
JP2010519313A (ja) 2010-06-03
WO2008103947A3 (en) 2008-11-27
IL216778A0 (en) 2012-01-31
AU2008218184A1 (en) 2008-08-28
IL200526A0 (en) 2010-04-29
EP2129692A2 (en) 2009-12-09
AU2008218184B2 (en) 2013-01-10
ZA200906618B (en) 2010-06-30

Similar Documents

Publication Publication Date Title
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
MX2009008926A (es) Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
PH12017501417A1 (en) Anti-fap antibodies and methods of use
IL244803B (en) Human anti-beta antibodies and their use
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
HK1136847A1 (en) Targeted integration into the ppp1r12c locus
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
MX2010006576A (es) Composiciones y metodos para producir isopreno.
MX2009003938A (es) Anticuerpos e inmunoconjugados y sus usos.
MX2013007168A (es) Anticuerpo anti-pcsk9 y metodos de uso.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
MX2011007930A (es) Conjugados de insulina cristalina.
UA110103C2 (uk) Модифікований туберкульозний антиген
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX339083B (es) Proteinas de enlace a cd127.
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
MX2012009564A (es) ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2009013170A (es) Particulas de silice y metodos para prepararlas y utilizarlas.
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
WO2009135019A3 (en) Methods and compositions for prostate cancer immunotherapy

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal